Clinical Study
The Clinical Effect of Oral Vitamin D2 Supplementation on Psoriasis: A Double-Blind, Randomized, Placebo-Controlled Study
Table 3
Laboratory test results at the 3-month and 6-month follow-ups.
| Laboratory tests | Vitamin D2 | Placebo | p-value |
| At 3 months | | | | Serum 25(OH)D level (ng/mL) | 26.61±6.38 | 24.38±7.89 | 0.34 | Vitamin D status classification | | | 0.07 | Deficiency, n(%) | 2(9.5%) | 7(41.2%) | | Insufficiency, n(%) | 15(71.4%) | 8(47.1%) | | Adequacy, n(%) | 4(19.0%) | 2(11.8%) | | Parathyroid hormone level (pg/mL) | 63.09±21.47 | 55.15±22.15 | 0.27 | Calcium level (mg/dL) | 8.83±0.47 | 9.07±0.43 | 0.12 | Phosphorus level (mg/dL) | 3.2±0.56 | 3.9±1.52 | 0.10 | CRP level (mg/L) | 3.61±3.62 | 3.54±3.92 | 0.96 | CRP change (mg/L) | -3.2482±6.24 | -0.84±3.88 | 0.08 | Creatinine level (mg/dL) | 0.88±0.23 | 0.87±0.22 | 0.90 | Albumin level (mg/L) | 3.97±0.38 | 3.99±0.35 | 0.81 | At 6 months | | | | Serum 25(OH)D level (ng/mL) | 27.39±5.89 | 22.44±7.28 | 0.029 | Vitamin D status classification | | | 0.003 | Deficiency, n(%) | 0(0.0%) | 7(43.8%) | | Insufficiency, n(%) | 17(81.0%) | 7(43.8%) | | Adequacy, n(%) | 4(19.0%) | 2(12.5%) | | Parathyroid hormone level (pg/mL) | 52.65±18.87 | 49.13±13.55 | 0.54 | Calcium level (mg/dL) | 9.12±0.29 | 9.19±0.30 | 0.46 | Phosphorus level (mg/dL) | 3.61±0.74 | 3.41±0.32 | 0.35 | CRP level (mg/L) | 5.67±7.35 | 3.99±0.32 | 0.46 | CRP change (mg/L) | -1.03±9.07 | 0.30±3.01 | 0.58 | Creatinine level (mg/dL) | 0.88±0.23 | 0.87±0.22 | 0.90 | Albumin level (mg/L) | 3.97±0.38 | 3.99±0.35 | 0.81 |
|
|
Continuous data are mean ± standard deviation (SD); CRP, C-reactive protein. |